Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT
2025-522215-42-00Phase 4Withdrawn
- Sponsor
- Rigshospitalet
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of hydrocortisone sodium succinate, Alkindi Sprinkle, acetylcysteine and ferric derisomaltose in bacterial disease and viral infection (2 arms), sponsored by Rigshospitalet. Primary endpoint: Days alive and out of hospital at 14 days post-randomization (DAOH-14). Planned start Dec 2025; status: withdrawn.
02
Drugs
hydrocortisone sodium succinateAlkindi Sprinkleacetylcysteineferric derisomaltose
03
Conditions
bacterial diseaseviral infection
Beyond the preview
Go deeper on 2025-522215-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522215-42-00.